CALL US:022-6101 1700   sales@saffronmedia.in
HOME NEWS INGREDIENT MART EVENTS TOPICS INTERVIEW EDIT
 
News
 
Shardul Nautiyal, Mumbai September 25 , 2024
Alkomex Pharma Intl., a rising leader in the global pharmaceutical and healthcare industry, is expanding into Indian and Southeast Asian markets with its healthcare products and solutions considering India’s resilient value supply chain.
 
Alex Meneses Vega, CEO of Alkomex Pharma, highlighted the company’s potential to advance global health solutions by blending Indian and international research, along with the commercialization of its products through contract research organizations (CROs) and contract manufacturing in pharmaceuticals, health products, and cosmetics.

“We see tremendous opportunity to create innovative global health solutions through a combination of Indian and international expertise. By leveraging the strength of Indian research and our global commercial network, we are positioned to not only boost exports but also establish a resilient supply chain,” stated Vega.

Founded in Chile in 2007 and now headquartered in Rockland, New York, Alkomex Pharma has been steadily expanding its reach across multiple continents. The company first ventured into India in 2013 for packaging solutions and began exporting to the country a year later in 2014. Today, the company partners with key players in India, supplying a range of products, including ophthalmic and dermatological solutions, multivitamins, and probiotics, with a significant partnership in place with the Danone Group.

“We supply India through contract manufacturing, focusing on ophthalmic, derma, and healthcare products. The Indian pharma sector is highly receptive to Good Manufacturing Practices (GMP), and we’ve built a robust supply chain with partners like Vinco Laboratories. Our products not only serve Indian markets but also extend to the US and Germany, where we are commercializing oncology products,” explained Felipe Meneses P, general manager of Alkomex GBN.

In addition to its Indian operations, Alkomex Pharma has established logistics centers and quality control laboratories in Chile, with strong export ties to countries like Peru, and is expanding its presence in Southeast Asia.

Meneses, a seasoned leader, has also been instrumental in setting up a pharmaceutical expert committee modeled after Pharmexcil of India, aimed at boosting exports and strengthening supply chain resilience. “This committee will help us support the growth of global health solutions, and we are committed to building strong relationships across the regions we serve,” Meneses said.

Meneses further emphasized the role of his son - Felipe Meneses P, a business administrator with a master’s in supply chain management and expertise in data analytics, who has been key in driving Alkomex Pharma’s supply chain innovations. “My son’s technical skills in data analytics and supply chain management are helping us scale our operations and optimize global distribution,” Meneses noted, highlighting the family’s deep involvement in the company’s continued success.

"As Alkomex Pharma continues its international expansion, it remains committed to delivering innovative healthcare solutions that bridge continents and improve patient outcomes across the globe. With an ever-expanding network of partners, a focus on cutting-edge research, and a robust supply chain, the company is poised for long-term success in the competitive global pharmaceutical market," Felipe Meneses P stated.

Share This Story

Leave a Reply
Your name (required)   Your email (required)
 
Website (required)
CommenT
Enter Code (Required)

 

 

 
INGREDIENT MART

RECENT NEWS

TOPICS
That foods might provide therapeutic benefits is clearly not a new concept. ...

 

MAIN LINKS OUR SERVICES OTHER PRODUCTS ONLINE MEDIA  
 
About Us
Contact Us
News Archives
 

Product Finder
Features and Articles
News
 
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
 
Media Information
Rate Card
Advertise
 
 
Copyright © 2023 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Chrome (103.0) or Firefox (90.0)